LivaNova PLC (LIVN)
LIVN trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1639691/000163969126000010/0001639691-26-000010-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | LIVN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United Kingdom |
| IPO year | Not reported by the screener |
| SEC CIK | 0001639691 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Incorporated in | United Kingdom |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.4B |
| Net income | -$242.5M |
| Operating income | $199.4M |
| Net margin | -17.5% |
| Operating margin | 14.4% |
| Revenue growth | +10.7% |
| Cash | $635.6M |
| Total assets | $2.6B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $563.5M cash; operating cash flow $59.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 55,086,809 (2026-10-28); 54,605,527 a year earlier; 53,870,826 three years earlier. | Cover page 2026-10-28 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Houston, Texas, United States | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $393.1M | $34.3M | $73.7M | $563.5M | $295.4M | $1.5B | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $390.6M | $108.6M | $66.6M | $516.6M | $290.1M | $1.5B | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $362.3M | $22.3M | $15.2M | $539.7M | $285.3M | $1.4B | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $360.9M | $30.9M | $82.4M | $635.6M | $376.1M | $1.4B | 10-K 2026-02-25 |
| Q3 2025 2025-09-30 | $357.8M | $26.8M | $85.1M | $646.1M | $434.5M | $1.3B | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $352.5M | $27.2M | $62.9M | $593.6M | $430.6M | $1.3B | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $316.9M | -$327.3M | $24.0M | $738.4M | $628.2M | $1.3B | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $321.8M | $55.9M | $78.7M | $428.9M | $627.0M | $1.3B | 10-K 2026-02-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2021-08-05 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 957 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.5% |
| 1 month | +19.6% |
| 3 months | +11.1% |
| Year to date | +48.4% |
| 1 year | +65.4% |
| From 52-week high | -3.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AXGN | Axogen Inc. | $55.38 | -0.98% | $3.3B |
| TMDX | TransMedics Group Inc. | $92.21 | +0.91% | $3.2B |
| CNMD | CONMED Corporation | $49.35 | -2.45% | $1.5B |
| CBLL | CeriBell Inc. | $26.42 | +1.07% | $1.0B |
| INMD | InMode Ltd. | $13.15 | -0.90% | $755.9M |
| CV | CapsoVision Inc. | $6.47 | +7.30% | $346.9M |
| MDT | Medtronic plc. | $102.88 | +0.02% | $131.6B |
| ELMD | Electromed Inc. | $23.10 | -5.02% | $188.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier